AAAAAA
Results:
1-17
|
Results: 17
Authors:
Luzio, SD
Lucas, I
Owens, DR
Citation: Sd. Luzio et al., Importance of validation of immunoassays for intact proinsulin, CLIN CH L M, 39(7), 2001, pp. 631-633
Authors:
Hovorka, R
Albarrak, A
Chassin, L
Luzio, SD
Playle, R
Owens, DR
Citation: R. Hovorka et al., Relationship between beta-cell responsiveness and fasting plasma glucose in Caucasian subjects with newly presenting Type 2 diabetes, DIABET MED, 18(10), 2001, pp. 797-802
Authors:
Owens, DR
Zinman, B
Bolli, GB
Citation: Dr. Owens et al., Insulins today and beyond, LANCET, 358(9283), 2001, pp. 739-746
Authors:
Luzio, SD
Anderson, DM
Owens, DR
Citation: Sd. Luzio et al., Effects of timing of administration and meal composition on the pharmacokinetic and pharmacodynamic characteristics of the short-acting oral hypoglycemic agent nateglinide in healthy subjects, J CLIN END, 86(10), 2001, pp. 4874-4880
Authors:
Perrott, RL
North, RV
Drasdo, N
Ahmed, KA
Owens, DR
Citation: Rl. Perrott et al., The influence of plasma glucose upon pulsatile ocular blood flow in subjects with Type II diabetes mellitus, DIABETOLOG, 44(6), 2001, pp. 700-705
Authors:
Owens, DR
McDougall, A
Citation: Dr. Owens et A. Mcdougall, Repaglinide: prandial glucose regulation in clinical practice, DIABET OB M, 2, 2000, pp. S43-S48
Authors:
Owens, DR
Gibbins, RL
Kohner, E
Grimshaw, GM
Greenwood, R
Harding, S
Citation: Dr. Owens et al., Diabetic retinopathy screening, DIABET MED, 17(7), 2000, pp. 493-494
Authors:
Owens, DR
Coates, PA
Luzio, SD
Tinbergen, JP
Kurzhals, R
Citation: Dr. Owens et al., Pharmacokinetics of I-125-labeled insulin glargine (HOE 901) in healthy men - Comparison with NPH insulin and the influence of different subcutaneousinjection sites, DIABET CARE, 23(6), 2000, pp. 813-819
Authors:
Owens, DR
Luzio, SD
Ismail, I
Bayer, T
Citation: Dr. Owens et al., Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes, DIABET CARE, 23(4), 2000, pp. 518-523
Authors:
Bolli, GB
Owens, DR
Citation: Gb. Bolli et Dr. Owens, Insulin glargine, LANCET, 356(9228), 2000, pp. 443-445
Authors:
Close, CF
Collins, A
Gregory, W
Goodwin, A
Hill, C
Jarrett, RJ
Jones, SL
Keen, H
Scott, GS
Viberti, G
Vora, H
Yip, J
Grenfell, A
Sampson, MJ
Watkins, PJ
Fishwick, C
Gatling, W
Hill, RD
Marshall, SM
Coates, P
Owens, DR
Peters, JR
Vora, J
Warren, S
Citation: Cf. Close et al., Predictors of the development of microalbuminuria in patients with Type 1 diabetes mellitus: a seven-year prospective study, DIABET MED, 16(11), 1999, pp. 918-925
Authors:
Ollerton, RL
Playle, R
Luzio, SD
Owens, DR
Citation: Rl. Ollerton et al., Underdiagnosis of type 2 diabetes by use of American Diabetes Association criteria, DIABET CARE, 22(4), 1999, pp. 649-650
Authors:
Ollerton, RL
Playle, R
Ahmed, K
Dunstan, FD
Luzio, SD
Owens, DR
Citation: Rl. Ollerton et al., Day-to-day variability of fasting plasma glucose in newly diagnosed type 3diabetic subjects, DIABET CARE, 22(3), 1999, pp. 394-398
Authors:
Owens, DR
Citation: Dr. Owens, Repaglinide: a new short-acting insulinotropic agent for the treatment of Type 2 diabetes, EUR J CL IN, 29, 1999, pp. 30-37
Authors:
George, LD
Lusty, J
Owens, DR
Ollerton, RL
Citation: Ld. George et al., Effect of software manipulation (Photoshop) of digitised retinal images onthe grading of diabetic retinopathy, BR J OPHTH, 83(8), 1999, pp. 911-913
Authors:
Owens, DR
Citation: Dr. Owens, Repaglinide - Prandial glucose regulator: A new class of oral antidiabeticdrugs, DIABET MED, 15(12), 1998, pp. S28-S36
Authors:
Owens, DR
Citation: Dr. Owens, Repaglinide - Prandial glucose regulator: A new class of oral antidiabeticdrugs, DIABET MED, 15(12), 1998, pp. S28-S36
Risultati:
1-17
|